【24h】

Treatment of acute pancreatitis: focus on medical care.

机译:急性胰腺炎的治疗:注重医疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Acute pancreatitis has an incidence of about 300 per 1 million individuals per year, of which 10-15% of patients develop the severe form of the disease. Novel management options, which have the potential to improve outcome, include initial proper fluid resuscitation, which maintains microcirculation and thereby potentially decreases ischaemia and reperfusion injury. The traditional treatment concept in acute pancreatitis, fasting and parenteral nutrition, has been challenged and early initiation of enteral feeding in severe pancreatitis and oral intake in mild acute pancreatitis is both feasible and provides some benefits. There are at present no data supporting immunonutritional supplements and probiotics should be avoided in patients with acute pancreatitis. There is also no evidence of any benefits provided by prophylactic antibacterials in patients with predicted severe acute pancreatitis. A variety of specific medical interventions have been investigated (e.g. intense blood glucose monitoring by insulin) but none has become clinically useful. Lessons can probably be learned from critical care in general, but studies are needed to verify these interventions in acute pancreatitis.
机译:急性胰腺炎每年的发病率约为每百万人中300例,其中10-15%的患者发展为严重的疾病。可能改善治疗效果的新型治疗方案包括初始适当的液体复苏,以维持微循环,从而潜在地减少局部缺血和再灌注损伤。急性胰腺炎,禁食和肠胃外营养的传统治疗观念受到了挑战,严重胰腺炎中肠内营养的早期开始和轻度急性胰腺炎的口服摄入都是可行的,并提供了一些好处。目前尚无支持免疫营养补充剂的数据,急性胰腺炎患者应避免使用益生菌。也没有证据表明预防性抗菌药物对预计患有严重急性胰腺炎的患者有任何益处。已经研究了多种具体的医学干预措施(例如,通过胰岛素进行严格的血糖监测),但是没有一种在临床上有用。一般而言,可以从重症监护中汲取经验教训,但需要进行研究以验证对急性胰腺炎的这些干预措施。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号